

Certificate of Analysis

BTK (R28H), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-765, 14-765-K, 14-765M

Parent Lot # 2067978

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant, full-length, human BTK containing the R28H mutation. Expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose.

R28H is one of a number of mutations in BTK shown to cause X-linked agammaglobulinemia (XLA), an immune deficiency disorder characterized by a lack of mature, immunoglobulin-producing, peripheral B cells (Ohta *et al.*, (1994), Proc. Natl. Acad. Sci. USA, **91**, 9062-9066; Hyvonen & Saraste, (1997), EMBO J. **16**, 3396-3404). Purity 57.3% by SDS-PAGE and Coomassie blue staining. MW = 78.4kDa.

Specific Activity (Parent lot# 2067978): 21U/mg, where one unit of BTK (R28H), active activity is defined as 1nmol phosphate incorporated into 300µM LKBtide (LSNLYHQGKFLQTFGSPPLYRRR) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.441mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 25–551ng of this lot of enzyme phosphorylated 300µM LKBtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as BTK with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **LKBtide (LSNLYHQGKFLQTFCGSPLYRRR):** Use at a final assay concentration of 300 μ M. Prepare a 3mM stock and add 2.5 μ l of stock per assay point.
3. **NaCl:** Use at a final assay concentration of 50mM. Make a 3M stock. Add 0.42 μ l of stock per assay point.
4. **Triton X-100:** Make up a 10% (w/v) stock. Add 2.5 μ l of stock per assay point
5. **BTK (R28H), active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 25–551ng per assay point.
6. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per well.
2. Add 2.5 μ l of **LKBtide**.
3. Add **2.5 μ l (25–551ng) BTK (R28H), active**.
4. Add 0.42 μ l of 3M NaCl
5. Add 2.5 μ l of 10% (w/v) Triton X-100.
6. Make up to 15 μ l with dH₂O.
7. Add 10 μ l of diluted [γ -³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
10. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 50mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

BTK (R28H) Sequence Information

<u>Protein</u>	human BTK (R28H)
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M16 of the recombinant protein is equivalent to M1 of human BTK (R28H)
<u>Accession number</u>	GenBank NM_000061

Recombinant BTK amino acid sequence:

```

1  MHHHHHEFEK  GLRRRMAAVI  LESIFLKRSQ  QKKKTSPLNF  KKHLFLLTVH  KLSYYEYDFE
61  RRRGSKKGS   IDVEKITCVE  TVVPEKNPPP  ERQIPRRGEE  SSEMEQISII  ERFYPYFQV
121 YDEGPLYVFS  PTEELRKRWI  HQLKNVIRYN  SDLVQKYHPC  FWIDGQYLCC  SQTAKNAMGC
181 QILENRNGSL  KPGSSHRKTK  KPLPPTPEED  QILKKPLPPE  PAAAPVSTSE  LKKVVVALYDY
241 MPMNANDLQL  RKGDEYFILE  ESNLPWWRAR  DKNQGEGYIP  SNYVTEAEDS  IEMYEWYSKH
301 MTRSQAELL  KQEGKEGGFI  VRDSSKAGKY  TVSVFAKSTG  DPQGVIRHYV  VCSTPQSQYY
361 LAEKHLFSTI  PELINYHQHN  SAGLISRLKY  PVSQQKNAP  STAGLGYGSW  EIDPKDLTFL
421 KELGTGQFGV  VKYGKWRGQY  DVAIKMIKEG  SMSDEFIEE  AKVMMNLSHE  KLVQLYGVCT
481 KQRPIFIITE  YMANGCLLNY  LREMRHRFQT  QQLLEMCKDV  CEAMEYLESK  QFLHRDLAAR
541 NCLVNDQGVV  KVSDFGLSRY  VLDDEYTSSV  GSKFPVRWSP  PEVLMYSKFS  SKSDIWAFFV
601 LMWEIYSLGK  MPYERFTNSE  TAEHIAQGLR  LYRPHLASEK  VYTIMYSCWH  EKADERPTFK
661 ILLSNILDVM  DEES

```

Recombinant BTK nucleotide sequence:

```

1  atgcatcatc  accatcacca  tgaattcaaa  ggcctacgtc  gacgaatggc  cgcagtgatt
61  ctggagagca  tctttctgaa  gcgatcccaa  cagaaaaaga  aaacatcacc  tctaaacttc
121 aagaagcacc  tgtttctctt  gaccgtgcac  aaactctcct  actatgagta  tgactttgaa
181 cgtgggagaa  gaggcagtaa  gaagggttca  atagatgttg  agaagatcac  ttgtgttgaa
241 acagtggttc  ctgaaaaaaaa  tcctcctcca  gaaagacaga  ttccgagaag  aggtgaagag
301 tccagtgaaa  tggagcaaat  ttcaatcatt  gaaaggttcc  cttatccctt  ccaggttgta
361 tatgatgaag  ggcctctcta  cgtcttctcc  ccaactgaag  aactaaggaa  gcggtggatt
421 caccagctca  aaaacgtaat  ccggtacaac  agtgatctgg  ttcagaaata  tcacccttgc
481 ttctggatcg  atgggcagta  tctctgctgc  tctcagacag  ccaaaaatgc  tatgggctgc
541 caaatTTTgg  agaacaggaa  tggaaagtta  aaacctggga  gttctcaccg  gaagacaaaa
601 aagcctcttc  cccaacgcc  tgaggaggac  cagatcttga  aaaagccact  accgcctgag
661 ccagcagcag  caccagtctc  cacaagtgag  ctgaaaaagg  ttgtggccct  ttatgattac
721 atgccaatga  atgccaatga  tctacagctg  cggaagggtg  atgaatattt  tatcttggag
781 gaaagcaact  tacatggtg  gagagcacga  gataaaaatg  ggcaagagg  ctacattcct
841 agtaactatg  tactgaagc  agaagactcc  atagaaatgt  atgagtggta  ttccaaacac
901 atgactcgga  gtcaggctga  gcaactgcta  aagcaagagg  ggaaagaagg  aggtttcatt
961 gtcagagact  ccagcaaaagc  tggcaaatat  acagtgtctg  tgtttgctaa  atccacaggg
1021 gaccctcaag  ggggtgatac  tcattatggt  gtgtgttcca  cacctcagag  ccagtattac
1081 ctggctgaga  agcacctttt  cagcaccatc  cctgagctca  ttaactacca  tcagcacaac
1141 tctgcaggac  tcatatccag  gctcaaatat  ccagtgtctc  aacaaaacaa  gaatgcacct
1201 tccactgcag  gcctgggata  cggatcatgg  gaaattgatc  caaaggacct  gaccttcttg
1261 aaggagctgg  ggactggaca  atttggggta  gtgaagtatg  ggaaatggag  aggccagtac
1321 gacgtggcca  tcaagatgat  caaagaaggc  tccatgtctg  aagatgaatt  cattgaagaa
1381 gccaaagtca  tgatgaatct  ttcccatgag  aagctggtgc  agttgtatgg  cgtctgcacc
1441 aagcagcgc  ccatcttcat  catcactgag  tacatggcca  atggctgcct  cctgaactac
1501 ctgagggaga  tgcgccaccg  cttccagact  cagcagctgc  tagagatgtg  caaggatgtc
1561 tgtgaagcca  tggaatacct  ggagtcaaag  cagttccttc  accgagacct  ggagctcga
1621 aactgtttgg  taaacgatca  aggagtgtgt  aaagtatctg  atttcggcct  gtccaggtat

```

Certificate of Analysis

```
1681 gtcctggatg atgaatacac aagctcagta ggctccaaat ttccagtccg gtggtcccca
1741 ccggaagtcc tgatgtatag caagttcagc agcaaactctg acatttgggc ttttggggtt
1801 ttgatgtggg aaatttactc cctggggaag atgccatatg agagatttac taacagtgag
1861 actgctgaac acattgcca aggcctacgt ctctacaggc ctcatctggc ttcagagaag
1921 gtatatacca tcatgtacag ttgttggcat gagaaagcag atgagcgtcc cacttttaa
1981 attcttctga gcaatattct agatgtcatg gatgaagaat cctga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services